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Background
The HIV-1 envelope protein gp41 has been shown to play
critical roles in the viral mucosal transmission and infec-
tion of CD4+ cells. Gag is a structural protein configuring
the viral capsid, and has been suggested to constitute a tar-
get of cellular immunity potentially controlling viral load.
Methods
The goal of this project is to express in plants enveloped
virus-like particles (eVLPs) consisting of Gag and a
''deconstructed'' version of gp41 (dgp41) as a broad-act-
ing mucosal immunogen.
Results
Using a PCR-based de novo gene synthesis method, a plant
optimized HIV-1 gag gene was constructed. The gene was
expressed in Nicotiana benthamiana using a modified
tobacco mosaic virus-based transient expression system
and leaf accumulation of the 55 kDa Gag protein was con-
firmed. Sucrose gradient sedimentation showed that the
full-length Gag protein migrated at a density correspond-
ing to that reported for Gag VLPs. Furthermore, examina-
tion of leaf material and the extract in transmission
electron microscopy showed budding of 100-nm VLPs.
Stable lines harboring the gag gene were created and were
shown to accumulate the Gag protein. The dgp41 gene was
then transiently expressed in these stable lines, and
expression was confirmed with western blotting using
anti-2F5 Abs. Preliminary evidence based on sucrose gra-
dient sedimentation suggests that the two proteins may
assemble into eVLPs.
Conclusion
These results suggest that plant cells can support the for-
mation of HIV-1 dgp41/Gag eVLPs.
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